Concomitant use of diuretics and SGLT2i in HF
Video navigation menu
- Mechanistic study of 14 days 01:39
- Mechanistic study of 6 weeks 04:12
- Analyses of Emperor-Reduced and DAPA-HF 06:06
- Conclusions 09:47
This presentation was broadcasted at the e-SPACE CRM conference, a global web-conference on the cardio-renal-metabolic syndrome, that was held January 22-24, 2021.
The post hoc analysis of DAPA-HF on the effect of SGLT2i on risk of hyperkalemia associated with MRA use in HFrEF has now been published.
Prof. Patrick Rossignol, MD - Professor of Therapeutics at the University of Lorraine, France.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: